Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux vs low molecular weight heparin for autoimmune recurrent pregnancy loss
ChiCTR2100046209Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Apr 2021
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of fondaparinux and low molecular weight heparin calcium in recurrent miscarriage (RPL), systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) and 2 more (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Abortion rate and Live birth rate. Started Apr 2021; status: recruiting.
02
Drugs
fondaparinuxlow molecular weight heparin calcium
03
Conditions
recurrent miscarriage (RPL)systemic lupus erythematosus (SLE)antiphospholipid syndrome (APS)Undifferentiated Connective Tissue Disease (UCTD)Sjögren's syndrome
Beyond the preview
Go deeper on ChiCTR2100046209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046209.